Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Bibliographic Details
Main Authors:	Fioretto, Paola, Stefansson, Bergur V., Johnsson, Eva, Cain, Valerie A., Sjöström, C. David
Format:	Online
Language:	English
Published:	Springer Berlin Heidelberg 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969341/

Similar Items

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
by: Heerspink, H. J. L., et al.
Published: (2016)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
by: Fioretto, Paola, et al.
Published: (2015)

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
by: Kohan, Donald E, et al.
Published: (2014)

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
by: Fioretto, Paola, et al.
Published: (2016)

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
by: Yavin, Yshai, et al.
Published: (2016)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
by: van der Walt, J-S, et al.
Published: (2013)

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
by: Ptaszynska, Agata, et al.
Published: (2015)

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
by: Sonesson, Christian, et al.
Published: (2016)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
by: Chang, Yoon-Kyung, et al.
Published: (2016)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
by: Chang, Yoon-Kyung, et al.
Published: (2016)

Urinary Angiopoietin-2 Is Associated with Albuminuria in Patients with Type 2 Diabetes Mellitus
by: Chen, Shan, et al.
Published: (2015)

Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen
by: Stefánsson, Bergur V., et al.
Published: (2011)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
by: Kuecker, Catherine M, et al.
Published: (2016)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
by: Mori, Hiroko, et al.
Published: (2013)

Cardiovascular autonomic function tests in type 2 diabetes mellitus with micro albuminuria
by: Nurhayati Yusoff
Published: (2012)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
by: Tamez, Hector E., et al.
Published: (2015)

Albuminuria - marker of progressive renal disease
by: Stoian, M, et al.
Published: (2012)

Renal Tube Casts without Albuminuria
Published: (1908)

Not so critical appraisal of dapagliflozin
by: Doggrell, Sheila A
Published: (2014)

Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16‐week double‐blind treatment period
by: Araki, Eiichi, et al.
Published: (2016)

Plasma Lipoprotein(a) Levels Are Associated with Mild Renal Impairment in Type 2 Diabetics Independent of Albuminuria
by: Lin, Jennie, et al.
Published: (2014)

Albuminuria and the Duration of Albuminuria in Cholera
by: Brahmachari, U. N.
Published: (1907)

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials
by: Sun, Yu-nan, et al.
Published: (2014)

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
by: Fumika Shigiyama, et al.
Published: (2017-07-01)

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
by: Li, Feng-fei, et al.
Published: (2016)

Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria
by: Velho, Gilberto, et al.
Published: (2013)

Hemodiafiltration Improves Plasma 25-Hepcidin Levels: A Prospective, Randomized, Blinded, Cross-Over Study Comparing Hemodialysis and Hemodiafiltration
by: Stefánsson, Bergur V., et al.
Published: (2012)

Dapagliflozin: BMS 512148; BMS-512148
Published: (2012)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
by: DeFronzo, Ralph A., et al.
Published: (2013)

Renal Structure in Normoalbuminuric and Albuminuric Patients With Type 2 Diabetes and Impaired Renal Function
by: Ekinci, Elif I., et al.
Published: (2013)

THE PRODUCTION OF ALBUMINURIA BY RENAL VASOCONSTRICTION IN ANIMALS AND IN MAN
by: Starr, Isaac
Published: (1926)

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
by: Chao, Edward C
Published: (2012)

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
by: Imamura, Akira, et al.
Published: (2013)

Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
by: Salvo, Marissa C, et al.
Published: (2014)

Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
by: Daniele, Giuseppe, et al.
Published: (2016)

Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
by: Saeed, Mujahid A, et al.
Published: (2014)

PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus
by: Li Zheng, et al.
Published: (2018-01-01)

Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
by: Mumin Alper Erdogan, et al.
Published: (2018-06-01)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
by: Whaley, Jean M, et al.
Published: (2012)

Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
by: Reilly, Timothy P., et al.
Published: (2014)